Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo

Journal of the American College of Surgeons

Volumn 187, Issue 3, 1998, Pages 295-306

  Shears II, Larry L ^a   Kibbe, Melina R ^a   Murdock, Alan D ^a   Billiar, Timothy R ^a   Lizonova, Alena ^c   Kovesdi, Imre ^c   Watkins, Simon C ^b   Tzeng, Edith ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c GENVEC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BINDING SITE; CELL PROLIFERATION; GENE OVEREXPRESSION; GENE TRANSFER; INHIBITION KINETICS; LEUKOCYTE ADHERENCE; NONHUMAN; PRIORITY JOURNAL; RAT; SWINE; VASCULAR SMOOTH MUSCLE;

ADENOVIRIDAE; ANIMALS; CAROTID ARTERIES; CELLS, CULTURED; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HYPERPLASIA; ILIAC ARTERY; MALE; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, SPRAGUE-DAWLEY; SWINE;

EID: 0031666110     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1072-7515(98)00163-X     Document Type: Article

References (50)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809.
2. Gibbons GH, Dzau VJ. Molecular therapies for vascular disease. Science 1996;272:689-693.
3. Palmer R, Ferrige MJ, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
4. Ignarro LJ, Buga GM, Wood KS, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265-9269.
5. Lamas S, Marsden PA, Li GI, et al. Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc Natl Acad Sci USA 1992; 89:6348-6352.
6. Radomski MW, Palmer RMJ, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987;92:639-646.
7. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991; 94:2036-2044.
8. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-1777.
9. Guo JP, Panday MM, Consigny PM, Lefer AM. Mechanisms of vascular preservation by a novel NO donor following rat carotid artery intimal injury. Am J Physiol 1995;269:H1122-131.
10. Chin JH, Azhar S, Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992; 89:10-18.
11. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 1991;87:432-438.
12. Schwartz SM, Stemerman MB, Benditt ER The aortic intima, II: repair of the aortic lining after mechanical denudation. Am J Pathol 1975;81:15-42.
13. Clowes AW, Clowes MM, Reidy MA. Kinetics of cellular proliferation after arterial injury, I: smooth muscle growth in the absence of endothelium. Lab Invest 1983;49:327-332.
14. Clowes AW, Clowes MM, Reidy MA. Kinetics of cellular proliferation after arterial injury, III: endothelial and smooth muscle growth in chronically denuded vessels. Lab Invest 1986;54:295-303.
15. Guo J, Milhoan KA, Tuan RS, Lefer AM. Beneficial effect of SPM-5185, a cysteine-containing nitric oxide donor, in rat carotid artery intimal injury. Circ Res 1994;75:77-84.
16. Marks DS, Vita JA, Folts JD, et al. Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Invest 1995;96:2630-2638.
17. LeeJS, Adrie C, Jacob HJ, et al. Chronic inhalation of nitric oxide inhibits neointimal formation after balloon-induced arterial injury. Circ Res 1996;78:337-342.
18. von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995; 92:1137-1141.
19. Schwartz SM, deBlois D, O'Brien ERM. The intima: soil for atherosclerosis and restenosis. Circ Res 1995;77:445-465.
20. Tzeng E, Shears LL, Robbins PD, et al. Vascular gene transfer of the human inducible nitric oxide synthase: characterization of activity and effects on myointimal hyperplasia. Mol Med 1996;2: 211-225.
21. Morris SM Jr, Billiar TR. New insights into the regulation of inducible nitric oxide synthesis. Am J Physiol 1994; 266:E829-839.
22. Wilson JM. Adenoviruses as gene delivery vehicle. N Engl J Med 1996;334:1185-1187.
23. Tzeng E, Shears LL, Lotze MT, Billiar TR. Gene therapy. Curr Probl Surg 1996;33:961-1052.
24. Geller DA, Lowenstein CJ, Shapiro RA, et al. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc Natl Acad Sci USA 1993;90:3491-3495.
25. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from a human adenovirus type 5. J Gen Virol 1977;36:59-72.
26. Stow ND. Cloning of a DNA fragment from the left-hand terminus of the adenovirus type 2 genome and its use in site-directed mutagenesis. J Virol 1981;37:171-180.
27. Geller DA, Nussler AK, Di Silvio M, et al. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc Natl Acad Sci USA 1993; 90: 522-526.
28. Davies P, Patton W Peripheral and central vascular smooth muscle cells from rat lung exhibit different cytoskeletal protein profiles but similar growth factor requirements. J Cell Physiol 1994; 159: 399-406.
29. Nakayama DK, Geller DA, Di Silvio M, et al. Tetrahydrobiopterin synthesis and inducible nitric oxide production in pulmonary artery smooth muscle. Am J Physiol 1994;266:L455-460.
30. Tzeng E, Yoneyama T, Hatakeyama K, et al. Vascular inducible nitric oxide synthase gene therapy: requirement for GTP cyclohydrolase I. Surgery 1996;120:315-321.
31. MacGregor GR, Mogg AE, Burke JF, Caskey CT Histochemical staining of clonal mammalian cell lines expressing E. coli beta galactosidase indicates heterogeneous expression of the bacterial gene. Somat Cell Mol Genet 1987;13:253-265.
32. 6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase. J Med Chem 1994;37:3886-3888.
33. Sheehan DC, Hrapchak BB. Theory and Practice of Histotechnology. St. Louis MO, CV Mosby Company, 1980:196-197.
34. 4B promotes assembly of enzyme subunits into an active dimer. Proc Natl Acad Sci USA 1995;92:11771-11775.
35. Baek KJ, Thiel BA, Lucas S, Stuehr DJ. Macrophage nitric oxide synthase subunits: purification, characterization, and role of prosthetic groups and substrate in regulating their association into a dimeric enzyme. J Biol Chem 1993;268:21120-21129.
36. Sims FH. A comparison of structural features of the walls of coronary arteries from 10 different species. Pathology 1989; 21:115-124.
37. Cornwell TL, Arnold E, Boerth NJ, Lincoln TM. Inhibition of smooth muscle cell growth by nitric oxide and activation of cGMP-dependent protein kinase by cGMP. Am J Physiol 1994; 267:C1405-1413.
38. Crystal RG, McElvaney NG, Rosenfeld MA, et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994; 8:42-51.
39. Hansson GK, Geng Y, Holm J, et al. Arterial smooth muscle cells express nitric oxide synthase in response to endothelial injury. J Exp Med 1994;180:733-738.
40. Akyurek LM, Fellstrom BC, Yan Z, et al. Inducible and endothelial nitric oxide synthase expression during development of transplant arteriosclerosis in rat aortic grafts. Am J Pathol 1996; 149: 1981-1990.
41. Shears LL II, Kawaharada N, Tzeng E, et al. Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J Clin Invest 1997;100:2035-2042.
42. Gross SS, Levi R. Tetrahydrobiopterin synthesis: an absolute requirement for cytokine-induced nitric oxide generation by vascular smooth muscle. J Biol Chem 1992;267:25722-25729.
43. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-143.
44. Stamler JS. Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell 1994;78:931-936.
45. Kim YM, de Vera ME, Watkins SC, Billiar TR. Nitric oxide protects cultured rat hepatocytes from tumor necrosis factor-alpha-induced apoptosis by inducing heat shock protein 70 expression. J Biol Chem 1997;272:1402-1411.
46. Tzeng E, Kim Y-M, Pitt BR, et al. Adenoviral transfer of the inducible nitric oxide synthase gene blocks endothelial cell apoptosis. Surgery 1997;122:255-263.
47. Ohno T, Gordon D, San H, et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994;265:781-784.
48. Chang MW, Barr E, Seltzer J, et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995;267:518-522.
49. Chang MW, Barr E, Lu MM, et al. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995;96:2260-2268.
50. Lancaster JR Jr. Simulation of the diffusion and reaction of endogenously produced nitric oxide. Proc Natl Acad Sci USA 1994;91: 8137-8141.